{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:09:40Z","timestamp":1785413380804,"version":"3.56.0"},"reference-count":32,"publisher":"IMR Press","issue":"7","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmazie"],"abstract":"<jats:p>Background:Since aging is associated with pharmacokinetic and pharmacodynamic changes, polypharmacy is particularly harmful in older adults. Meanwhile, clinical pharmacists contribute to safer prescribing by applying their clinical expertise during medication review. Therefore, this study aimed to characterize potential drug-related problems through the analysis of routine pharmaceutical interventions.Methods:Data were collected from the electronic health record between 2019 and 2025; potentially inappropriate medications and high-risk medications were identified. Drug-related problems were categorized according to the Pharmaceutical Care Network Europe classification.Results:Pharmacists performed 12,856 pharmaceutical interventions, of which prescribers accepted 65%. The mean patient age was 87.5 years (range, 65\u2013113 years), and 60.2% of patients were female. Among all pharmaceutical interventions, 1779 involved a potentially inappropriate medication. The most frequent causes of drug-related problems were related to dose selection (39.8%), drug selection (14.3%), treatment duration (10.1%), and treatment safety (9.3%). The most commonly targeted drug categories were the nervous system (24.7%), the digestive tract and metabolism (21.5%), blood and hematopoietic organs (19.8%), and the cardiovascular system (13.6%).Conclusions:Pharmaceutical interventions that prevent prescribing errors in older adults are essential in clinical practice. Understanding potential drug-related problems and the nature of pharmaceutical interventions can help ensure safe pharmacotherapy by alerting prescribers and caregivers to major medication-related risks.<\/jats:p>","DOI":"10.31083\/pharmazie53161","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:42:49Z","timestamp":1785411769000},"source":"Crossref","is-referenced-by-count":0,"title":["Pharmaceutical Interventions During Inpatient Care in a French Geriatric Hospital"],"prefix":"10.31083","volume":"81","author":[{"given":"Diana","family":"Lopez-Leret","sequence":"first","affiliation":[{"name":"Pharmacy, Hospital of Paul Doumer \u2013 Assistance Publique des H\u00f4pitaux de Paris, 60140 Labruy\u00e8re, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4443-8843","authenticated-orcid":true,"given":"Jo\u00ebl","family":"Schlatter","sequence":"additional","affiliation":[{"name":"Pharmacy, Hospital of Paul Doumer \u2013 Assistance Publique des H\u00f4pitaux de Paris, 60140 Labruy\u00e8re, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Wang Z, Liu T, Su Q, Luo H, Lou L, Zhao L, et al. Prevalence of Polypharmacy in Elderly Population Worldwide: A Systematic Review and Meta-Analysis. Pharmacoepidemiology and Drug Safety. 2024; 33: e5880.","DOI":"10.1002\/pds.5880"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatrics. 2017; 17: 230.","DOI":"10.1186\/s12877-017-0621-2"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Davies LE, Spiers G, Kingston A, Todd A, Adamson J, Hanratty B. Adverse Outcomes of Polypharmacy in Older People: Systematic Review of Reviews. Journal of the American Medical Directors Association. 2020; 21: 181\u2013187.","DOI":"10.1016\/j.jamda.2019.10.022"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Bonanno EG, Figueiredo T, Mimoso IF, Morgado MI, Carrilho J, Mid\u00e3o L, et al. Polypharmacy Prevalence Among Older Adults Based on the Survey of Health, Ageing and Retirement in Europe: An Update. Journal of Clinical Medicine. 2025; 14: 1330.","DOI":"10.3390\/jcm14041330"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. British Journal of Clinical Pharmacology. 2004; 57: 6\u201314.","DOI":"10.1046\/j.1365-2125.2003.02007.x"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Pazan F, Wehling M. Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences. European Geriatric Medicine. 2021; 12: 443\u2013452.","DOI":"10.1007\/s41999-021-00479-3"},{"key":"ref7","unstructured":"World Health Organization. Medication Safety in Polypharmacy (WHO\/UHC\/SDS\/2019.11). 2019. Available at: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/325454\/WHO-UHC-SDS-2019.11-eng.pdf?ua=1 (Accessed: 21 April 2026)"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Laroche ML, Guillaumin M, Grau M, Vettoretti L, Valnet-Rabier MB. Medication errors in older patients: a pharmacovigilance perspective. Drugs & Therapy Perspectives. 2024; 40: 276\u2013289.","DOI":"10.1007\/s40267-024-01090-9"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Isop LM, Neculau AE, Kramers CK, Dima L. Polypharmacy Intervention Studies in Older Adults: Challenges in Proving Benefits in Hard Clinical Outcomes. American Journal of Therapeutics. 2025; 32: e458\u2013e466.","DOI":"10.1097\/MJT.0000000000002010"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Ruiz-Ramos J, Hern\u00e1ndez MH, Juanes-Borrego AM, Mil\u00e0 R, Mangues-Bafalluy MA, Mestres C. The Impact of Pharmaceutical Care in Multidisciplinary Teams on Health Outcomes: Systematic Review and Meta-Analysis. Journal of the American Medical Directors Association. 2021; 22: 2518\u20132526.","DOI":"10.1016\/j.jamda.2021.05.038"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Stuhec M, Gorenc K, Zelko E. Evaluation of a collaborative care approach between general practitioners and clinical pharmacists in primary care community settings in elderly patients on polypharmacy in Slovenia: a cohort retrospective study reveals positive evidence for implementation. BMC Health Services Research. 2019; 19: 118.","DOI":"10.1186\/s12913-019-3942-3"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Chan M, Plakogiannis R, Stefanidis A, Chen M, Saraon T. Pharmacist-Led Deprescribing for Patients With Polypharmacy and Chronic Disease States: A Retrospective Cohort Study. Journal of Pharmacy Practice. 2023; 36: 1192\u20131200.","DOI":"10.1177\/08971900221097246"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Allenet B, Juste M, Mouchoux C, Collomp R, Pourrat X, Varin R, et al. De la dispensation au plan pharmaceutique personnalis\u00e9: vers un mod\u00e8le int\u00e9gratif de pharmacie clinique. Le Pharmacien Hospitalier et Clinicien. 2019; 54: 56\u201363.","DOI":"10.1016\/j.phclin.2018.12.003"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013; 310: 2191\u20132194.","DOI":"10.1001\/jama.2013.281053"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"By the 2023 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2023; 71: 2052\u20132081.","DOI":"10.1111\/jgs.18372"},{"key":"ref16","unstructured":"World Health Organization. Medication without harm. 2023. Available at: https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/1eacccb6-838e-4787-bfd9-4bdeb4debfcf\/content (Accessed: 21 April 2026)"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Dumitrescu I, Casteels M, De Vliegher K, Van Der Linden L, Van Leeuwen E, Dilles T. High-Risk Medication in Home Care Nursing: A Delphi Study. Journal of Patient Safety. 2022; 18: 435\u2013443.","DOI":"10.1097\/PTS.0000000000001023"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Dumitrescu I, Casteels M, De Vliegher K, Hubens C, Dilles T. Home Care Patient's Experiences and Medication Burden Related to High-Risk Medication Use: A Cross-Sectional Study. International Journal of Older People Nursing. 2025; 20: e70003.","DOI":"10.1111\/opn.70003"},{"key":"ref19","unstructured":"PCNE Pharmaceutical Care Network Europe. The definition of drug-related problems. 2020. Available at: https:\/\/pcne.org\/wp-content\/uploads\/2026\/01\/PCNE_classification_V9-1-en-2026.pdf (Accessed: 21 April 2026)"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Faramarzi Nasab N, Rezaeian S, Ezadi S, Khatony A. Prevalence and Determinants of Polypharmacy: A Cross-Sectional Study Among Elderly Patients With Cardiovascular Diseases in Outpatient Clinics. Scientifica. 2025; 2025: 6641747.","DOI":"10.1155\/sci5\/6641747"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Abu-Naser D. Impact of Clinical Pharmacist Interventions in Prescribing Errors in Hospitalized Diabetic Patients with Major Polypharmacy. Hospital Pharmacy. 2021; 56: 392\u2013399.","DOI":"10.1177\/0018578720985428"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Ciapponi A, Fernandez Nievas SE, Seijo M, Rodr\u00edguez MB, Vietto V, Garc\u00eda-Perdomo HA, et al. Reducing medication errors for adults in hospital settings. The Cochrane Database of Systematic Reviews. 2021; 11: CD009985.","DOI":"10.1002\/14651858.CD009985.pub2"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Doffou E, Coulibaly A, Abrogoua PD. Analysis of pharmaceutical interventions related to outpatient treatment of chronic heart failure. Annales Pharmaceutiques Francaises. 2025; 83: 739\u2013747.  (In French)","DOI":"10.1016\/j.pharma.2025.01.004"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Somers A, Robays H, De Paepe P, Van Maele G, Perehudoff K, Petrovic M. Evaluation of clinical pharmacist recommendations in the geriatric ward of a Belgian university hospital. Clinical Interventions in Aging. 2013; 8: 703\u2013709.","DOI":"10.2147\/CIA.S42162"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Bedouch P, Sylvoz N, Charpiat B, Juste M, Roubille R, Rose FX, et al. Trends in pharmacists' medication order review in French hospitals from 2006 to 2009: analysis of pharmacists' interventions from the Act-IP\u00a9 website observatory. Journal of Clinical Pharmacy and Therapeutics. 2015; 40: 32\u201340.","DOI":"10.1111\/jcpt.12214"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Alkanj A, Godet J, Johns E, Gourieux B, Michel B. Deep learning classification of drug-related problems from pharmaceutical interventions issued by hospital clinical pharmacists during medication prescription review: a large-scale descriptive retrospective study in a French university hospital. European Journal of Hospital Pharmacy: Science and Practice. 2025; 32: 324\u2013328.","DOI":"10.1136\/ejhpharm-2024-004139"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Ducoffe AR, Baehr A, Pe\u00f1a JC, Rider BB, Yang S, Hu DJ. Adverse Drug Event Prevention: 2014 Action Plan Conference. American Journal of Medical Quality: the Official Journal of the American College of Medical Quality. 2016; 31: 476\u2013485.","DOI":"10.1177\/1062860615588105"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Sluggett JK, Harrison SL, Ritchie LA, Clough AJ, Rigby D, Caughey GE, et al. High-Risk Medication Use in Older Residents of Long-Term Care Facilities: Prevalence, Harms, and Strategies to Mitigate Risks and Enhance Use. The Senior Care Pharmacist. 2020; 35: 419\u2013433.","DOI":"10.4140\/TCP.n.2020.419"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"O'Mahony D, Cherubini A, Guiteras AR, Denkinger M, Beuscart JB, Onder G, et al. STOPP\/START criteria for potentially inappropriate prescribing in older people: version 3. European Geriatric Medicine. 2023; 14: 625\u2013632.","DOI":"10.1007\/s41999-023-00777-y"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Tasaka Y, Tanaka A, Yasunaga D, Asakawa T, Araki H, Tanaka M. Potential drug-related problems detected by routine pharmaceutical interventions: safety and economic contributions made by hospital pharmacists in Japan. Journal of Pharmaceutical Health Care and Sciences. 2018; 4: 33.","DOI":"10.1186\/s40780-018-0125-z"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Saldanha V, Randall Martins R, Lima SIVC, Batista de Araujo I, Gouveia Oliveira A. Incidence, types and acceptability of pharmaceutical interventions about drug related problems in a general hospital: an open prospective cohort. BMJ Open. 2020; 10: e035848.","DOI":"10.1136\/bmjopen-2019-035848"},{"key":"ref32","unstructured":"Journal officiel de la R\u00e9publique fran\u00e7aise. Arr\u00eat\u00e9 du 21 f\u00e9vrier 2023 relatif au Renouvellement et \u00e0 L\u2019adaptation des prescriptions par les pharmaciens exer\u00e7ant au sein des pharmacies \u00e0 usage int\u00e9rieur en application de L\u2019article L 5126-1 du code de la sant\u00e9 publique. 2023. Available at: https:\/\/www.legifrance.gouv.fr\/loda\/id\/JORFTEXT000047241696 (Accessed: 21 April 2026)"}],"container-title":["Die Pharmazie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/Pharmazie\/81\/7\/10.31083\/Pharmazie53161","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:42:54Z","timestamp":1785411774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/Pharmazie\/81\/7\/10.31083\/Pharmazie53161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"alternative-id":["S0031-7144(26)03372-0"],"URL":"https:\/\/doi.org\/10.31083\/pharmazie53161","relation":{},"ISSN":["0031-7144","3053-691X"],"issn-type":[{"value":"0031-7144","type":"print"},{"value":"3053-691X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"article-number":"53161"}}